Literature DB >> 30772682

GMP-compatible manufacturing of three iPS cell lines from human peripheral blood.

Alexandra Haase1, Wolfgang Glienke2, Lena Engels3, Gudrun Göhring4, Ruth Esser2, Lubomir Arseniev2, Ulrich Martin3.   

Abstract

The utilization of human induced pluripotent stem cells (hiPSCs) for disease modeling and drug discovery is already reality, and several first-in-man-applications as cellular therapeutics have been initiated. Implementation of good manufacturing practice (GMP)-compliant protocols for the generation of hiPSC lines is crucial to increase the application safety as well as to fulfil the legal requirements for clinical trials approval. Here we describe the development of a GMP-compatible protocol for the reprogramming of CD34+ hematopoietic stem cells from peripheral blood (CD34+ PBHSC) into hiPSCs using Sendai virus-based reprogramming vectors. Three GMP-compatible hiPSC (GMP-hiPSC) lines were manufactured and characterized under these conditions.
Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh：

Year:  2019        PMID： 30772682     DOI： 10.1016/j.scr.2019.101394

Source DB:  PubMed          Journal:  Stem Cell Res        ISSN： 1873-5061            Impact factor:   2.020


  9 in total

Review 1.  Using liver models generated from human-induced pluripotent stem cells (iPSCs) for evaluating chemical-induced modifications and disease across liver developmental stages.

Authors:  Celeste K Carberry; Stephen S Ferguson; Adriana S Beltran; Rebecca C Fry; Julia E Rager
Journal:  Toxicol In Vitro       Date:  2022-06-07       Impact factor: 3.685

Review 2.  Optimizing Generation of Stem Cell-Derived Islet Cells.

Authors:  Kevin Verhoeff; Nerea Cuesta-Gomez; Ila Jasra; Braulio Marfil-Garza; Nidheesh Dadheech; A M James Shapiro
Journal:  Stem Cell Rev Rep       Date:  2022-05-31       Impact factor: 6.692

3.  Chemically-Defined, Xeno-Free, Scalable Production of hPSC-Derived Definitive Endoderm Aggregates with Multi-Lineage Differentiation Potential.

Authors:  Anais Sahabian; Malte Sgodda; Ortwin Naujok; Rabea Dettmer; Julia Dahlmann; Felix Manstein; Tobias Cantz; Robert Zweigerdt; Ulrich Martin; Ruth Olmer
Journal:  Cells       Date:  2019-12-04       Impact factor: 6.600

4.  Transplantation of GMP-grade human iPSC-derived retinal pigment epithelial cells in rodent model: the first pre-clinical study for safety and efficacy in China.

Authors:  Hang Zhang; Bingnan Su; Luyan Jiao; Ze-Hua Xu; Chang-Jun Zhang; Jinfu Nie; Mei-Ling Gao; Ying V Zhang; Zi-Bing Jin
Journal:  Ann Transl Med       Date:  2021-02

5.  Process control and in silico modeling strategies for enabling high density culture of human pluripotent stem cells in stirred tank bioreactors.

Authors:  Felix Manstein; Kevin Ullmann; Wiebke Triebert; Robert Zweigerdt
Journal:  STAR Protoc       Date:  2021-12-09

6.  High density bioprocessing of human pluripotent stem cells by metabolic control and in silico modeling.

Authors:  Felix Manstein; Kevin Ullmann; Christina Kropp; Caroline Halloin; Wiebke Triebert; Annika Franke; Clara-Milena Farr; Anais Sahabian; Alexandra Haase; Yannik Breitkreuz; Michael Peitz; Oliver Brüstle; Stefan Kalies; Ulrich Martin; Ruth Olmer; Robert Zweigerdt
Journal:  Stem Cells Transl Med       Date:  2021-03-04       Impact factor: 6.940

7.  ReMeDy: a platform for integrating and sharing published stem cell research data with a focus on iPSC trials.

Authors:  Kirill Borziak; Irena Parvanova; Joseph Finkelstein
Journal:  Database (Oxford)       Date:  2021-06-22       Impact factor: 4.462

Review 8.  Clinical-Grade Human Pluripotent Stem Cells for Cell Therapy: Characterization Strategy.

Authors:  Daniela Rehakova; Tereza Souralova; Irena Koutna
Journal:  Int J Mol Sci       Date:  2020-03-31       Impact factor: 5.923

Review 9.  Induced Pluripotent Stem Cells in Dental and Nondental Tissue Regeneration: A Review of an Unexploited Potential.

Authors:  Israa Ahmed Radwan; Dina Rady; Marwa M S Abbass; Sara El Moshy; Nermeen AbuBakr; Christof E Dörfer; Karim M Fawzy El-Sayed
Journal:  Stem Cells Int       Date:  2020-03-29       Impact factor: 5.443
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.